{"ticker": {"uuid": "b5562b07-7c28-40d3-9eca-d661ba65693a", "symbol": "DJNJ3", "name": "Johnson & Johnson", "exchange": "BUE", "country": "AR", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results", "summary": "MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Ob", "url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "source_link": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T12:00:00+00:00", "published_display": "13 Aug 2026 12:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Dilution risk"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.121805, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 98.6, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Fda Approval", "Gene Therapy", "Net Income"], "evidence_basis": "", "score_included": true}, {"title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T21:13:16+00:00", "published_display": "12 Aug 2026 21:13", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Beat expectations", "Operating growth", "Negative market reaction", "Positive valuation view"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.260338, "evidence_share": 5.0, "evidence_share_display": "5", "freshness_pct": 90.0, "age_days": 0.8, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Medical Equipment", "Revenue Growth", "Share Price", "Shareholder", "Split"], "evidence_basis": "", "score_included": true}, {"title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "summary": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:20:01+00:00", "published_display": "12 Aug 2026 17:20", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 64, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.157102, "evidence_share": 3.0, "evidence_share_display": "3", "freshness_pct": 88.0, "age_days": 0.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Growth Rate", "Guidance", "Healthcare", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "The Energy and Pharma Giants Quietly Funding HDV\u2019s 3% Yield, and How Safe Each One Is", "summary": "Quick Read XOM and JNJ earn 'Very Safe' dividend ratings inside HDV, backed by interest coverage of 56x and 64 consecutive annual raises. AbbVie's Skyrizi and Rinvoq are replacing Humira faster than expected, but Net Debt/EBITDA of 2.3x keeps a watchlist tag on its dividend. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout. Energy and pharma names account for the top four", "url": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T16:12:28+00:00", "published_display": "12 Aug 2026 16:12", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 77, "tone_signals": ["Guidance raised", "Balance sheet strengthened"], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.260579, "evidence_share": 5.0, "evidence_share_display": "5", "freshness_pct": 90.8, "age_days": 1.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Credit Rating", "Dividends", "ETF", "Energy", "Free Cash Flow"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care", "summary": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T16:11:41+00:00", "published_display": "12 Aug 2026 16:11", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Operating growth", "Growth forecast"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.194212, "evidence_share": 3.7, "evidence_share_display": "3.7", "freshness_pct": 87.4, "age_days": 1.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["Cardiovascular", "Clinical Trials", "Medtech", "Neuroscience", "Pharmaceuticals", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\"", "summary": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart. Analyst Suraj Kalia said the change reflects \"a more nuanced risk-reward assessment at these levels.\" On the positive side, the firm views U.S. competition as a \"non-factor,\" with field checks suggesting \"some unique workflow challenges for Ottava that limit long-term appeal\" and real-estate issues for Hugo. It added that Intuitive's customized price-volume contracts complicate c", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "source_link": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:59:31+00:00", "published_display": "12 Aug 2026 12:59", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 75, "tone_signals": ["Analyst upgrade"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.132708, "evidence_share": 2.5, "evidence_share_display": "2.5", "freshness_pct": 77.5, "age_days": 1.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Healthcare", "Price Target", "Robotic Surgery", "Upgrade Downgrade"], "evidence_basis": "", "score_included": true}, {"title": "Why Revolution Medicines May Be Big Pharma\u2019s Next Takeover Target", "summary": "Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform ", "url": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "source_link": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:50:24+00:00", "published_display": "12 Aug 2026 12:50", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Positive financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.091002, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 77.4, "age_days": 1.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "M A", "Oncology", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "summary": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:25:19+00:00", "published_display": "12 Aug 2026 12:25", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Beat expectations"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.118249, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 77.0, "age_days": 1.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Price Target", "Robotic Surgery", "Upgrade Downgrade"], "evidence_basis": "", "score_included": true}, {"title": "Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors", "summary": "Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (\"J&J\") and is a member of J&J's Executive Committee, where he leads research and development across oncology, immunology, neuroscie", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "source_link": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:00:00+00:00", "published_display": "12 Aug 2026 12:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 58, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.119284, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 89.3, "age_days": 1.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Fda Approval", "Mash", "Press Releases"], "evidence_basis": "", "score_included": true}, {"title": "If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever", "summary": "Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically recommended the Vanguard S&P 500 ETF because of its ultra-low fees, and it could help investors achieve a secure retirement. 10 stocks we like better than Vanguard S&P 500 ETF \u203a Warren Buffett served as chief executive officer of the Berkshire Hathaway(NYSE: BRKA)(NYSE: BRKB) holding company between 1965 and 2025", "url": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "source_link": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-12T09:17:00+00:00", "published_display": "12 Aug 2026 09:17", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 47, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.046713, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 64.6, "age_days": 1.3, "influence_label": "Low", "duplicate_count": 3, "topics": ["Diversification", "Etfs", "Financial Planning", "Long Term Investment", "Markets", "Tech"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Highlights Arista Networks (ANET) Following Q2 Beat and 50% Rally", "summary": "Arista Networks, Inc. (NYSE:ANET) posted $3.04 billion in total sales for Q2 2026, which represents a 37.7% year-over-year increase and beat Wall Street consensus estimates by $210 million. Non-GAAP earnings per share came in at $1.02, topping expectations by $0.13. The top-line expansion pulled the stock out of a mid-summer consolidation phase as hyperscalers accelerated hardware deployments for AI data centers. Jim Cramer Highlights AI Demand and 50% Rally On the August 5 episode of CNBC's Mad Money, host Jim Cramer pointed to Arista Networks, Inc.'s (NYSE:ANET) execution in high-speed data ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-highlights-arista-networks-180524380.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-highlights-arista-networks-180524380.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T18:05:24+00:00", "published_display": "11 Aug 2026 18:05", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Beat expectations", "Guidance raised", "Margin pressure", "Positive valuation view"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.205746, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 76.9, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["AI", "Consensus Estimate", "Data Centers", "Earnings", "Earnings Per Share", "Guidance"], "evidence_basis": "", "score_included": true}, {"title": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?", "summary": "AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory", "url": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_link": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:54:00+00:00", "published_display": "11 Aug 2026 16:54", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 91, "tone_signals": ["Beat expectations", "Improving financial comparison", "Strong Demand", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.270681, "evidence_share": 5.2, "evidence_share_display": "5.2", "freshness_pct": 76.4, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Immunology"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Jim Cramer Weighs In on Sentiment Shifts Driving Accenture and Cognizant Rallies", "summary": "On Monday's CNBC Mad Money episode, host Jim Cramer examined the top-performing stocks in the S&P 500, focusing on the dramatic turnaround in IT consulting leaders Cognizant Technology Solutions Corporation (NASDAQ:CTSH) and Accenture plc (NYSE:ACN). Addressing how market sentiment shifted around the \"AI displacement trade,\" Cramer outlined how both stocks surged despite long-standing Wall Street skepticism: I want to focus on the 10 best and 10 worst performers of the S&P 500, give you a better sense of the situation; maybe there's some opportunities here for you. When you look at the biggest", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-weighs-sentiment-shifts-165245860.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-weighs-sentiment-shifts-165245860.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:52:45+00:00", "published_display": "11 Aug 2026 16:52", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 58, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.097685, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 76.4, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["AI", "Earnings", "Earnings Report", "It Consulting", "Market Sentiment", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus", "summary": "Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporting management's target of over $5B in peak annual sales. Alan Bash, interim CEO following Ying Huang's departure, emphasized continuity as Wall Street's $52 consensus target sits well above current share prices. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Legend Biotech didn't make the cut. Grab the names FREE today. Sh", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-gains-6-q2-165026094.html", "source_link": "https://finance.yahoo.com/healthcare/articles/legend-biotech-gains-6-q2-165026094.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:50:26+00:00", "published_display": "11 Aug 2026 16:50", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 90, "tone_signals": ["Beat expectations", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.267141, "evidence_share": 5.1, "evidence_share_display": "5.1", "freshness_pct": 76.4, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Car T", "Clinical Trials", "Earnings", "Net Income"], "evidence_basis": "archived_article", "score_included": true}, {"title": "These stocks have some of Wall Street\u2019s lowest short interest", "summary": "[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares outstanding, highlighting companies with relatively limited bearish positioning. Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) has the lowest short interest in the screen at 1.00%, followed by Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) and InnIO (INIO [https://seekingalpha.com/symbol/INIO]) at", "url": "https://seekingalpha.com/news/4629729-these-stocks-have-some-of-wall-streets-lowest-short-interest?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629729-these-stocks-have-some-of-wall-streets-lowest-short-interest?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-11T13:40:28+00:00", "published_display": "11 Aug 2026 13:40", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.03388, "evidence_share": 0.6, "evidence_share_display": "0.6", "freshness_pct": 48.7, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Consumer Goods", "Energy", "Financials", "Shares Outstanding", "Short Interest", "Technology"], "evidence_basis": "", "score_included": true}, {"title": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?", "summary": "Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa", "url": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:12:00+00:00", "published_display": "11 Aug 2026 13:12", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.172257, "evidence_share": 3.3, "evidence_share_display": "3.3", "freshness_pct": 74.8, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Innovative Medicine", "Litigation", "Medtech", "Patent Expiration", "Share Price"], "evidence_basis": "", "score_included": true}, {"title": "The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run", "summary": "Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue competition. The dV5 supercycle is early, with only 1,700 of nearly 13,000 total systems upgraded and over 100 platform updates still planned. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. ", "url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:09:39+00:00", "published_display": "11 Aug 2026 13:09", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 81, "tone_signals": ["Beat expectations", "Margin expansion", "Operating growth"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.201073, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 74.8, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Earnings", "Healthcare", "Share Buyback", "Split", "Surgical Robotics"], "evidence_basis": "", "score_included": true}, {"title": "The Galien Foundation Announces 2026 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\"", "summary": "A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo \"We are proud to recog", "url": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 62, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.118983, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 81.2, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Fda Approval", "Pharmaceuticals", "Rare Diseases"], "evidence_basis": "", "score_included": true}, {"title": "What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders", "summary": "In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these developments highlight Johnson & Johnson's effort to reposition around higher-growth innovative medicines and me", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-ottava-fda-002047054.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-ottava-fda-002047054.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T00:20:47+00:00", "published_display": "11 Aug 2026 00:20", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.119922, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 69.4, "age_days": 2.6, "influence_label": "Low", "duplicate_count": 3, "topics": ["Fda Approval", "Litigation", "Medtech", "Oncology", "Revenue Growth", "Robotics"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?", "summary": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:36:57+00:00", "published_display": "10 Aug 2026 22:36", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Guidance raised", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.199403, "evidence_share": 3.8, "evidence_share_display": "3.8", "freshness_pct": 68.7, "age_days": 2.7, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Growth", "Earnings Per Share", "Guidance", "Healthcare", "Medical Devices"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?", "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 \u2060billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong ", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T20:49:59+00:00", "published_display": "10 Aug 2026 20:49", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Strong Demand"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.197611, "evidence_share": 3.8, "evidence_share_display": "3.8", "freshness_pct": 68.0, "age_days": 2.8, "influence_label": "Low", "duplicate_count": 3, "topics": ["Diagnostics", "Earnings", "Earnings Growth", "Earnings Per Share", "Guidance", "Healthcare"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY", "summary": "During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the\u2026 Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these\u2026 I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a", "url": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:07:30+00:00", "published_display": "10 Aug 2026 18:07", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.089167, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 67.0, "age_days": 2.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "Fourth Quarter", "Healthcare", "M A"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance", "summary": "On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC's Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That's the big medical technology and supply play... That was formerly known as Becton, Dickson. This was the first full quarter after they split off their biosciences and diagnostics business, something we loved. They posted a 9-cent earnings beat off a $3.14 basis, higher-than-expected revenue, up 5.4% year-over-year. They also said their full-year revenue growth would be toward ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-sees-cheap-valuation-175313326.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-sees-cheap-valuation-175313326.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:53:13+00:00", "published_display": "10 Aug 2026 17:53", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 91, "tone_signals": ["Beat expectations", "Guidance raised", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.235685, "evidence_share": 4.5, "evidence_share_display": "4.5", "freshness_pct": 66.9, "age_days": 2.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Earnings", "Earnings Per Share", "Fourth Quarter", "Free Cash Flow", "Guidance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "The \u201cSet It & Forget It\u201d Stocks I\u2019d Want to Own", "summary": "Quick Read SBAC tops the group at a 2.58% yield, while JNJ's 64-year dividend streak and AAA credit rating make both core income holdings. $100,000 split equally across all four stocks generates $2,304 in annual passive income, a 2.30% blended yield that compounds as each company raises payouts. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Passive income is the ballast that keeps a portfolio steady when paychecks get interrupted. Layoffs, medical bills, or a ma", "url": "https://finance.yahoo.com/markets/stocks/articles/set-forget-stocks-d-want-170014127.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/set-forget-stocks-d-want-170014127.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:00:14+00:00", "published_display": "10 Aug 2026 17:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Improving financial comparison", "Operational disruption"], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.167246, "evidence_share": 3.2, "evidence_share_display": "3.2", "freshness_pct": 74.8, "age_days": 2.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Credit Rating", "Dividends", "Free Cash Flow", "Healthcare"], "evidence_basis": "", "score_included": true}, {"title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "summary": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "source_link": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:42:00+00:00", "published_display": "10 Aug 2026 14:42", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 79, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.114905, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 65.7, "age_days": 3.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Fda Approval", "Guidance", "Medical Instruments", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight", "summary": "The major depressive disorder market is experiencing a significant transformation as rapid-acting therapies with novel mechanisms of action complement conventional SSRIs and SNRIs. Recent treatment approvals have broadened therapeutic choices for patients with TRD and those who do not achieve adequate benefit from standard antidepressants. Meanwhile, pipeline candidates such as Seltorexant (Johnson & Johnson), Azetukalner (Xenon Pharmaceuticals), Itruvone (VistaGen), and others are advancing through clinical development to deliver improved efficacy, faster symptom relief, and better tolerabili", "url": "https://finance.yahoo.com/healthcare/articles/major-depressive-disorder-market-predicted-143100937.html", "source_link": "https://finance.yahoo.com/healthcare/articles/major-depressive-disorder-market-predicted-143100937.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:31:00+00:00", "published_display": "10 Aug 2026 14:31", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Guidance raised"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.126793, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 74.0, "age_days": 3.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Antidepressants", "Clinical Trials", "Major Depressive Disorder", "Market Research Reports", "Pharmaceuticals"], "evidence_basis": "", "score_included": true}, {"title": "Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava\u2019s FDA Approval?", "summary": "Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differ", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:42:42+00:00", "published_display": "10 Aug 2026 12:42", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.0453, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 64.9, "age_days": 3.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Fda Approval", "Financial Results", "Healthcare", "Medtech", "Robotic Surgery"], "evidence_basis": "", "score_included": true}, {"title": "3 Beaten-Down Healthcare Stocks to Buy in August", "summary": "Quick Read LLY grew Q1 revenue 56% and won FDA approval for the first oral GLP-1 pill, yet still trades 6% off its 52-week high. Healthcare has trailed SPY's 8% YTD gain, but JNJ's 64-year dividend streak and 20x forward P/E keep it compelling for value investors. ABBV's Skyrizi and Rinvoq surged 31% and 23%, more than offsetting Humira's decline while supporting a 53-year consecutive dividend increase streak. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Year t", "url": "https://finance.yahoo.com/healthcare/articles/3-beaten-down-healthcare-stocks-120055911.html", "source_link": "https://finance.yahoo.com/healthcare/articles/3-beaten-down-healthcare-stocks-120055911.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:00:55+00:00", "published_display": "10 Aug 2026 12:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Guidance raised", "Improving financial comparison", "Deteriorating financial comparison", "Contract or approval won"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.1239, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 64.7, "age_days": 3.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Dividends", "Earnings", "Fda Approval", "Healthcare", "Pharma"], "evidence_basis": "", "score_included": true}, {"title": "ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers", "summary": "Agreement supports ACCESS-affiliated ASCs in adopting the CARTO\u2122 System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers (ASC) across the United States. The agreement encompasses an integrated portfolio of three-dim", "url": "https://finance.yahoo.com/healthcare/articles/access-announces-multi-strategic-agreement-110000847.html", "source_link": "https://finance.yahoo.com/healthcare/articles/access-announces-multi-strategic-agreement-110000847.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T11:00:00+00:00", "published_display": "10 Aug 2026 11:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 71, "tone_signals": ["Operating growth"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.02485, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 33.1, "age_days": 3.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Ambulatory Surgery Centers", "Cardiovascular Care", "Electrophysiology"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson (JNJ) Stock Analysis: Evaluating Its 5.11% Potential Upside", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+%28JNJ%29+Stock+Analysis%3A+Evaluating+Its+5.11%25+Potential+Upside%22+%22DirectorsTalk+Interviews%22", "source_link_is_lookup": true, "source_name": "DirectorsTalk Interviews", "published_at": "2026-08-10T09:16:36+00:00", "published_display": "10 Aug 2026 09:16", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023958, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 32.3, "age_days": 3.3, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.", "summary": "Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we like better than Johnson & Johnson \u203a It's certainly not the market's most exciting stock, and not its highest-yielding one either. If you want reliable dividend growth, though, you'd be hard-pressed to find a better option than drugmaker Johnson & Johnson(NYSE: JNJ). In fact, after 64 straight years of annual dividend increases --", "url": "https://www.nasdaq.com/articles/johnson-johnson-has-increased-its-dividend-64-consecutive-years-heres-how-much-10000", "source_link": "https://www.nasdaq.com/articles/johnson-johnson-has-increased-its-dividend-64-consecutive-years-heres-how-much-10000", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-09T13:35:00+00:00", "published_display": "09 Aug 2026 13:35", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Improving financial comparison", "Capital returned"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.143065, "evidence_share": 2.7, "evidence_share_display": "2.7", "freshness_pct": 66.8, "age_days": 4.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Acquisitions", "Dividends", "Markets", "Oncology", "Pharmaceuticals"], "evidence_basis": "", "score_included": true}, {"title": "How Much Do You Need Invested to Out-Earn the Average Social Security Check With Dividends?", "summary": "Quick Read Replacing the $24,000 average Social Security check with dividends requires $685,000 at a 3.5% yield, $400,000 at 6%, or $240,000 at a risky 10%. A 3.5% yield growing 8% annually doubles income in 9 years, while a flat 10% yield stagnates and often erodes principal over time. The 10-year Treasury at 4.6% generates $24,000 with roughly $518,000 invested, setting the real risk-adjusted benchmark any dividend strategy must beat. Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor ha", "url": "https://finance.yahoo.com/markets/stocks/articles/much-invested-earn-average-social-213708497.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/much-invested-earn-average-social-213708497.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T21:37:08+00:00", "published_display": "08 Aug 2026 21:37", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Improving financial comparison", "Deteriorating financial comparison", "Capital returned"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.076194, "evidence_share": 1.5, "evidence_share_display": "1.5", "freshness_pct": 51.8, "age_days": 4.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Dividends", "Growth Rate", "Income", "Retirement", "Treasuries", "Yield"], "evidence_basis": "", "score_included": true}, {"title": "Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?", "summary": "Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic \u203a Medtronic(NYSE: MDT) and Intuitive Surgical(NASDAQ: ISRG), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there ", "url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "source_link": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-08T21:20:00+00:00", "published_display": "08 Aug 2026 21:20", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 75, "tone_signals": ["Beat expectations", "Improving financial comparison", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.113668, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 51.7, "age_days": 4.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["Competition", "Dividends", "Earnings", "Earnings Growth", "Earnings Per Share", "Earnings Release"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Is Telling Investors to Accumulate SpaceX for the Long Term", "summary": "During CNBC's Mad Money episode aired on August 5, Jim Cramer addressed investor concerns surrounding Space Exploration Technologies Corp. (NASDAQ:SPCX) and its immense capital requirements. Explaining why he remains bullish on SpaceX's long-term trajectory despite the massive expenditures involved, Cramer stated: I want to take this moment to explain why the stock might be valuable years down the road. Again, with the caveat that I don't know how many years or even which road, but you know what? It doesn't matter. I'm not being facetious here. This is Elon Musk we're talking about, quite poss", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-telling-investors-accumulate-200218837.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-telling-investors-accumulate-200218837.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T20:02:18+00:00", "published_display": "08 Aug 2026 20:02", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Positive valuation view", "Negative valuation view"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023919, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 18.9, "age_days": 4.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Investing", "Launch Systems", "Satellites", "Space", "Telecom"], "evidence_basis": "", "score_included": true}, {"title": "SA Asks: What's the outlook for Big Pharma M&A?", "summary": "[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth", "url": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T19:28:35+00:00", "published_display": "08 Aug 2026 19:28", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 34, "tone_signals": ["Operating deterioration"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.058471, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 62.0, "age_days": 4.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biotech", "Fda Approval", "M&a", "M A", "Oncology", "Pharma"], "evidence_basis": "", "score_included": true}, {"title": "Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech", "summary": "Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 stocks we like better than Intuitive Surgical \u203a Intuitive Surgical(NASDAQ: ISRG) can be hard to own because the stock is prone to deep drawdowns. It is in a drawdown right now, with the stock down roughly 40% from its early 2025 high. Even after that drop, the price-to-earnings ratio remains lofty at 42x. Th", "url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "source_link": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-08T16:35:00+00:00", "published_display": "08 Aug 2026 16:35", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.111084, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 50.3, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["Competition", "Growth Investing", "Growth Stocks", "Healthcare", "Markets", "Recurring Revenue"], "evidence_basis": "", "score_included": true}, {"title": "iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?", "summary": "Key Points iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total return of 80.2% but a significantly deeper maximum drawdown. iShares Global Healthcare ETF provides international exposure to major pharmaceutical and healthcare companies, while the State Street fund uses an equal-weighted U.S. biotech strategy.10 stocks we like better than iShares Trust - iShares Global Healthcare ETF \u203a Investors choosing between iShares Glob", "url": "https://www.nasdaq.com/articles/ishares-global-healthcare-etf-vs-state-street-spdr-biotech-etf-which-healthcare-focused", "source_link": "https://www.nasdaq.com/articles/ishares-global-healthcare-etf-vs-state-street-spdr-biotech-etf-which-healthcare-focused", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-08T16:22:01+00:00", "published_display": "08 Aug 2026 16:22", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 38, "tone_signals": ["Deteriorating financial comparison"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.052402, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 50.2, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["Biotech", "Dividends", "Etfs", "Healthcare", "Markets", "Pharmaceutical"], "evidence_basis": "", "score_included": true}, {"title": "Why PG, JNJ, and KO Could Surprise Investors Next Year", "summary": "Quick Read PG and JNJ target $180 and $300 respectively, with JNJ's oncology pipeline posting drug growth up to 83% in Q1. KO's FIFA World Cup 2026 activation across 180+ markets, paired with Zero Sugar volume up 16%, builds the case for $100. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Defensive blue chips rarely dominate headlines, but heading into 2027, three of the market's most reliable dividend payers stand out as durable compounders.Kenneth C. Zirkel / ", "url": "https://finance.yahoo.com/markets/stocks/articles/why-pg-jnj-ko-could-160053178.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/why-pg-jnj-ko-could-160053178.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T16:00:53+00:00", "published_display": "08 Aug 2026 16:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 88, "tone_signals": ["Beat expectations", "Guidance raised", "Raised Guidance", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.142925, "evidence_share": 2.7, "evidence_share_display": "2.7", "freshness_pct": 50.1, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Consumer Staples", "Dividends", "Earnings", "Free Cash Flow", "Healthcare", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?", "summary": "Key Points Vanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF. State Street Health Care Select Sector SPDR ETF is slightly more cost-effective with an expense ratio of 0.08% versus 0.09% for the Vanguard fund. While Vanguard Health Care ETF has higher 1-year total returns, State Street Health Care Select Sector SPDR ETF has achieved higher overall growth for a $1,000 investment over the last five years.10 stocks we like better than Vanguard World Fund - Vanguard Health Care ETF \u203a The State ", "url": "https://www.nasdaq.com/articles/vanguard-health-care-etf-vs-state-street-xlv-which-etf-better-buy-investors-2026", "source_link": "https://www.nasdaq.com/articles/vanguard-health-care-etf-vs-state-street-xlv-which-etf-better-buy-investors-2026", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-08T15:53:01+00:00", "published_display": "08 Aug 2026 15:53", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.008756, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 17.8, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Dividends", "ETF", "Healthcare", "Markets", "Share Price"], "evidence_basis": "", "score_included": true}, {"title": "The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?", "summary": "Quick Read A blended portfolio made up of two-thirds dividend growth at 3.5% and one-third income at 6% generates $56,000 annually from $1.25M, beating the 4% rule without touching principal. Dividend growers like JNJ and AMGN raising payouts at 6% annually double retirement income in roughly 12 years without adding new capital. mREITs and BDCs yielding 10%+ risk NAV erosion and recession-driven distribution cuts, effectively turning a $1.25M nest egg into a self-liquidating annuity. Many financial professionals are salespeople paid on what they push, not whether you end up wealthier. A fiduci", "url": "https://finance.yahoo.com/markets/stocks/articles/4-rule-vs-dividend-paycheck-230556163.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/4-rule-vs-dividend-paycheck-230556163.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T23:05:56+00:00", "published_display": "07 Aug 2026 23:05", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Operating growth"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.053357, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 45.5, "age_days": 5.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Dividends", "Income Strategy", "Retirement", "Wealth Management", "Yield Curve"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company's talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to o", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-reaches-5-191035095.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-reaches-5-191035095.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:10:35+00:00", "published_display": "07 Aug 2026 19:10", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 59, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.054244, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 56.0, "age_days": 5.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Balance Sheet", "Consumer Health", "Legal Issues", "Settlement"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson Dividend Stock Analysis: 64 Years of Increases and Current Valuation - News and Statistics", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+Dividend+Stock+Analysis%3A+64+Years+of+Increases+and+Current+Valuation+-+News+and+Statistics%22+%22IndexBox%22", "source_link_is_lookup": true, "source_name": "IndexBox", "published_at": "2026-08-05T09:08:25.492959+00:00", "published_display": "05 Aug 2026 09:08", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024851, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 31.8, "age_days": 8.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson stock holds just above $250.92 support as conflicting signals persist: weekly analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPbGhXUHpPWk1pNUNyWVduTy1zZEZRdEhNZTZnbTVkWTNvZXdtZjZSVll0cXpKUktZcTBtTnNmUVNYQ3QzOEdYYmF1dnBRZlo5eGY2cmUxckFsT1ZSdG1NVVVLTFVSV0JZOGJxQVZUYy1maWFycGVrX1FOUy1sbXg3VkFpa2htUl9VZjVrTE5FaFk?oc=5", "source_link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPbGhXUHpPWk1pNUNyWVduTy1zZEZRdEhNZTZnbTVkWTNvZXdtZjZSVll0cXpKUktZcTBtTnNmUVNYQ3QzOEdYYmF1dnBRZlo5eGY2cmUxckFsT1ZSdG1NVVVLTFVSV0JZOGJxQVZUYy1maWFycGVrX1FOUy1sbXg3VkFpa2htUl9VZjVrTE5FaFk?oc=5", "source_link_is_lookup": false, "source_name": "Traders Union", "published_at": "2026-08-04T14:13:36+00:00", "published_display": "04 Aug 2026 14:13", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00232, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 4.3, "age_days": 9.1, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson (JNJ) Stock Analysis: Here\u2019s Why Investors Are Eyeing A 5.73% Upside", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+%28JNJ%29+Stock+Analysis%3A+Here%E2%80%99s+Why+Investors+Are+Eyeing+A+5.73%25+Upside%22+%22DirectorsTalk+Interviews%22", "source_link_is_lookup": true, "source_name": "DirectorsTalk Interviews", "published_at": "2026-08-03T09:06:47+00:00", "published_display": "03 Aug 2026 09:06", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002113, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 2.8, "age_days": 10.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson makes $465 million equity investment in Sail Biomedicines", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+makes+%24465+million+equity+investment+in+Sail+Biomedicines%22+%22Bitget%22", "source_link_is_lookup": true, "source_name": "Bitget", "published_at": "2026-08-03T03:58:25.366157+00:00", "published_display": "03 Aug 2026 03:58", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001415, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 2.6, "age_days": 10.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson reaches $5.5 billion baby powder settlement", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+reaches+%245.5+billion+baby+powder+settlement%22+%22Reuters%22", "source_link_is_lookup": true, "source_name": "Reuters", "published_at": "2026-07-31T11:58:24.075473+00:00", "published_display": "31 Jul 2026 11:58", "source_kind": "editorial_wire", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000936, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 1.0, "age_days": 13.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+proposes+%245.5B+settlement+to+resolve+remaining+talc+litigation%22+%22Proactive+financial+news%22", "source_link_is_lookup": true, "source_name": "Proactive financial news", "published_at": "2026-07-29T10:28:25.299097+00:00", "published_display": "29 Jul 2026 10:28", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000275, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.5, "age_days": 15.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson stock trades steadily as diversified healthcare earnings support valuation", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+stock+trades+steadily+as+diversified+healthcare+earnings+support+valuation%22+%22AD+HOC+NEWS%22", "source_link_is_lookup": true, "source_name": "AD HOC NEWS", "published_at": "2026-07-27T03:58:25.135750+00:00", "published_display": "27 Jul 2026 03:58", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007291, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 8.9, "age_days": 17.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Why+Johnson+%26+Johnson+Is+Sending+Intuitive+Surgical+%28ISRG%29+Stock+Down+Today%22+%22Barchart.com%22", "source_link_is_lookup": true, "source_name": "Barchart.com", "published_at": "2026-07-23T22:07:57.580136+00:00", "published_display": "23 Jul 2026 22:07", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4.1e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 20.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Unusual Put Option Activity in Johnson & Johnson After JNJ Stock's Recent Runup", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Unusual+Put+Option+Activity+in+Johnson+%26+Johnson+After+JNJ+Stock%27s+Recent+Runup%22+%22Barchart.com%22", "source_link_is_lookup": true, "source_name": "Barchart.com", "published_at": "2026-07-21T09:28:23.758629+00:00", "published_display": "21 Jul 2026 09:28", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1.7e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 23.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson analyst consensus stays supportive, shares trade steadily on the NYSE", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+analyst+consensus+stays+supportive%2C+shares+trade+steadily+on+the+NYSE%22+%22ad-hoc-news.de%22", "source_link_is_lookup": true, "source_name": "ad-hoc-news.de", "published_at": "2026-07-20T03:58:23.724338+00:00", "published_display": "20 Jul 2026 03:58", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00023, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.3, "age_days": 24.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Dividend+King+vs.+Growth+Giant%3A+Johnson+%26+Johnson+Takes+on+Eli+Lilly%22+%22AOL.com%22", "source_link_is_lookup": true, "source_name": "AOL.com", "published_at": "2026-07-17T09:28:24.016688+00:00", "published_display": "17 Jul 2026 09:28", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001788, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 2.3, "age_days": 27.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "by_tier": {"direct": [{"title": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results", "summary": "MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Ob", "url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "source_link": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T12:00:00+00:00", "published_display": "13 Aug 2026 12:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "91092dc042f21d2049015aebad19a6bc538732ca2d40d3ea2ae4bb9e13730615", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.588, "provider_directional_mass": 0.138, "relevance_score": 0.636399, "entity_mapped": true, "sentiment_conflict": 0.462, "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Dilution risk"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.121805, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 98.6, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Fda Approval", "Gene Therapy", "Net Income"], "evidence_basis": "", "score_included": true}, {"title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T21:13:16+00:00", "published_display": "12 Aug 2026 21:13", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "c9437f7c9df7d454cc88beb6f60a9bfcb966bbe769c2cf6e3f76f9b179b4936b", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.783, "provider_directional_mass": 0.182, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.1, "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Beat expectations", "Operating growth", "Negative market reaction", "Positive valuation view"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.260338, "evidence_share": 5.0, "evidence_share_display": "5", "freshness_pct": 90.0, "age_days": 0.8, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Medical Equipment", "Revenue Growth", "Share Price", "Shareholder", "Split"], "evidence_basis": "", "score_included": true}, {"title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "summary": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:20:01+00:00", "published_display": "12 Aug 2026 17:20", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.667, "provider_directional_mass": 0.1079, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.534, "sentiment": "positive", "sentiment_pct": 64, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.157102, "evidence_share": 3.0, "evidence_share_display": "3", "freshness_pct": 88.0, "age_days": 0.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Growth Rate", "Guidance", "Healthcare", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "The Energy and Pharma Giants Quietly Funding HDV\u2019s 3% Yield, and How Safe Each One Is", "summary": "Quick Read XOM and JNJ earn 'Very Safe' dividend ratings inside HDV, backed by interest coverage of 56x and 64 consecutive annual raises. AbbVie's Skyrizi and Rinvoq are replacing Humira faster than expected, but Net Debt/EBITDA of 2.3x keeps a watchlist tag on its dividend. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout. Energy and pharma names account for the top four", "url": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T16:12:28+00:00", "published_display": "12 Aug 2026 16:12", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "dcf747a9ce3991456efb124defaa474880bc72c24deb26b5714a6ef69b7b8a84", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.731, "provider_directional_mass": 0.213, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.142, "sentiment": "positive", "sentiment_pct": 77, "tone_signals": ["Guidance raised", "Balance sheet strengthened"], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.260579, "evidence_share": 5.0, "evidence_share_display": "5", "freshness_pct": 90.8, "age_days": 1.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Credit Rating", "Dividends", "ETF", "Energy", "Free Cash Flow"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care", "summary": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T16:11:41+00:00", "published_display": "12 Aug 2026 16:11", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "9073c5771f91b89c5e6ebe007a507f5ff605ec1bb6a0376e88f53fbdfcbb6eb0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.71, "provider_directional_mass": 0.125, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.156, "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Operating growth", "Growth forecast"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.194212, "evidence_share": 3.7, "evidence_share_display": "3.7", "freshness_pct": 87.4, "age_days": 1.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["Cardiovascular", "Clinical Trials", "Medtech", "Neuroscience", "Pharmaceuticals", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\"", "summary": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart. Analyst Suraj Kalia said the change reflects \"a more nuanced risk-reward assessment at these levels.\" On the positive side, the firm views U.S. competition as a \"non-factor,\" with field checks suggesting \"some unique workflow challenges for Ottava that limit long-term appeal\" and real-estate issues for Hugo. It added that Intuitive's customized price-volume contracts complicate c", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "source_link": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:59:31+00:00", "published_display": "12 Aug 2026 12:59", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "51d09f49a249edf74240a838044ca42e1d3db275594bc2a3bd21270e54e907de", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.649, "provider_directional_mass": 0.122, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 75, "tone_signals": ["Analyst upgrade"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.132708, "evidence_share": 2.5, "evidence_share_display": "2.5", "freshness_pct": 77.5, "age_days": 1.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Healthcare", "Price Target", "Robotic Surgery", "Upgrade Downgrade"], "evidence_basis": "", "score_included": true}, {"title": "Why Revolution Medicines May Be Big Pharma\u2019s Next Takeover Target", "summary": "Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform ", "url": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "source_link": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:50:24+00:00", "published_display": "12 Aug 2026 12:50", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "fe4e389d770d2e29836a7265fb0b54c990f811b726528a98df8a2831a7b0d9f0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.527, "provider_directional_mass": 0.156, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Positive financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.091002, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 77.4, "age_days": 1.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "M A", "Oncology", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "summary": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:25:19+00:00", "published_display": "12 Aug 2026 12:25", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "93a8437a003e42bdc1cec61e325e382b08164d5e79e56bcc2ecbd8cc4c72cb21", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.613, "provider_directional_mass": 0.1141, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Beat expectations"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.118249, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 77.0, "age_days": 1.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Price Target", "Robotic Surgery", "Upgrade Downgrade"], "evidence_basis": "", "score_included": true}, {"title": "Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors", "summary": "Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (\"J&J\") and is a member of J&J's Executive Committee, where he leads research and development across oncology, immunology, neuroscie", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "source_link": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:00:00+00:00", "published_display": "12 Aug 2026 12:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "7f86b5227bc22a9752a278a909c94b778e142bfa5917ec7e264a507df28aa63b", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.497, "provider_directional_mass": 0.16, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 58, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.119284, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 89.3, "age_days": 1.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Fda Approval", "Mash", "Press Releases"], "evidence_basis": "", "score_included": true}, {"title": "If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever", "summary": "Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically recommended the Vanguard S&P 500 ETF because of its ultra-low fees, and it could help investors achieve a secure retirement. 10 stocks we like better than Vanguard S&P 500 ETF \u203a Warren Buffett served as chief executive officer of the Berkshire Hathaway(NYSE: BRKA)(NYSE: BRKB) holding company between 1965 and 2025", "url": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "source_link": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-12T09:17:00+00:00", "published_display": "12 Aug 2026 09:17", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["nasdaq.com"], "source_kind": "publisher", "story_key": "ee2012b426ba5b32f8f9770cbf19ac68a207ef1594a8b2065c3c2e011868767c", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.496, "provider_directional_mass": 0.117, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 47, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.046713, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 64.6, "age_days": 1.3, "influence_label": "Low", "duplicate_count": 3, "topics": ["Diversification", "Etfs", "Financial Planning", "Long Term Investment", "Markets", "Tech"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Highlights Arista Networks (ANET) Following Q2 Beat and 50% Rally", "summary": "Arista Networks, Inc. (NYSE:ANET) posted $3.04 billion in total sales for Q2 2026, which represents a 37.7% year-over-year increase and beat Wall Street consensus estimates by $210 million. Non-GAAP earnings per share came in at $1.02, topping expectations by $0.13. The top-line expansion pulled the stock out of a mid-summer consolidation phase as hyperscalers accelerated hardware deployments for AI data centers. Jim Cramer Highlights AI Demand and 50% Rally On the August 5 episode of CNBC's Mad Money, host Jim Cramer pointed to Arista Networks, Inc.'s (NYSE:ANET) execution in high-speed data ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-highlights-arista-networks-180524380.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-highlights-arista-networks-180524380.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T18:05:24+00:00", "published_display": "11 Aug 2026 18:05", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "03e91d033436cb9ff27a8f512fea79bdd57f98e10e15f767453b3085468984ba", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.771, "provider_directional_mass": 0.138, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.307, "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Beat expectations", "Guidance raised", "Margin pressure", "Positive valuation view"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.205746, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 76.9, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["AI", "Consensus Estimate", "Data Centers", "Earnings", "Earnings Per Share", "Guidance"], "evidence_basis": "", "score_included": true}, {"title": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?", "summary": "AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory", "url": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_link": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:54:00+00:00", "published_display": "11 Aug 2026 16:54", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "090bf59cb125911962fc47d181504d1d44aae2d4f30ce5872c472af57718e668", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 91, "tone_signals": ["Beat expectations", "Improving financial comparison", "Strong Demand", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.270681, "evidence_share": 5.2, "evidence_share_display": "5.2", "freshness_pct": 76.4, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Immunology"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Jim Cramer Weighs In on Sentiment Shifts Driving Accenture and Cognizant Rallies", "summary": "On Monday's CNBC Mad Money episode, host Jim Cramer examined the top-performing stocks in the S&P 500, focusing on the dramatic turnaround in IT consulting leaders Cognizant Technology Solutions Corporation (NASDAQ:CTSH) and Accenture plc (NYSE:ACN). Addressing how market sentiment shifted around the \"AI displacement trade,\" Cramer outlined how both stocks surged despite long-standing Wall Street skepticism: I want to focus on the 10 best and 10 worst performers of the S&P 500, give you a better sense of the situation; maybe there's some opportunities here for you. When you look at the biggest", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-weighs-sentiment-shifts-165245860.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-weighs-sentiment-shifts-165245860.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:52:45+00:00", "published_display": "11 Aug 2026 16:52", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "9d52adff9a8390b685d6bb55477eab305a5710c45bd0088784d29e91965aca91", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.547, "provider_directional_mass": 0.1572, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.688, "sentiment": "positive", "sentiment_pct": 58, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.097685, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 76.4, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["AI", "Earnings", "Earnings Report", "It Consulting", "Market Sentiment", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus", "summary": "Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporting management's target of over $5B in peak annual sales. Alan Bash, interim CEO following Ying Huang's departure, emphasized continuity as Wall Street's $52 consensus target sits well above current share prices. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Legend Biotech didn't make the cut. Grab the names FREE today. Sh", "url": "https://finance.yahoo.com/healthcare/articles/legend-biotech-gains-6-q2-165026094.html", "source_link": "https://finance.yahoo.com/healthcare/articles/legend-biotech-gains-6-q2-165026094.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:50:26+00:00", "published_display": "11 Aug 2026 16:50", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "f2e06038afee25fab88099f64942b11c7f011fb1a6fc0f4cc80df88cacfb7b25", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 90, "tone_signals": ["Beat expectations", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.267141, "evidence_share": 5.1, "evidence_share_display": "5.1", "freshness_pct": 76.4, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Car T", "Clinical Trials", "Earnings", "Net Income"], "evidence_basis": "archived_article", "score_included": true}, {"title": "These stocks have some of Wall Street\u2019s lowest short interest", "summary": "[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares outstanding, highlighting companies with relatively limited bearish positioning. Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) has the lowest short interest in the screen at 1.00%, followed by Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) and InnIO (INIO [https://seekingalpha.com/symbol/INIO]) at", "url": "https://seekingalpha.com/news/4629729-these-stocks-have-some-of-wall-streets-lowest-short-interest?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629729-these-stocks-have-some-of-wall-streets-lowest-short-interest?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-11T13:40:28+00:00", "published_display": "11 Aug 2026 13:40", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "7f5c088723df7b819b9614cfbd7a36a08c678f5e2ff7c81ee0a148c342c985d6", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.491, "provider_directional_mass": 0.094, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.03388, "evidence_share": 0.6, "evidence_share_display": "0.6", "freshness_pct": 48.7, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Consumer Goods", "Energy", "Financials", "Shares Outstanding", "Short Interest", "Technology"], "evidence_basis": "", "score_included": true}, {"title": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?", "summary": "Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa", "url": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:12:00+00:00", "published_display": "11 Aug 2026 13:12", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "5eb3cb65a1afd2dc0743d89b3879c74fdfa3eb94c6a8bd6ff3878e319fe8cfaa", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.664, "provider_directional_mass": 0.194, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.149, "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.172257, "evidence_share": 3.3, "evidence_share_display": "3.3", "freshness_pct": 74.8, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Innovative Medicine", "Litigation", "Medtech", "Patent Expiration", "Share Price"], "evidence_basis": "", "score_included": true}, {"title": "The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run", "summary": "Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue competition. The dV5 supercycle is early, with only 1,700 of nearly 13,000 total systems upgraded and over 100 platform updates still planned. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. ", "url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:09:39+00:00", "published_display": "11 Aug 2026 13:09", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "1669df33eaba3e6eee9714c010f314c05d1e8287e8ce389932ee77aaead1dfe1", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.778, "provider_directional_mass": 0.125, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 81, "tone_signals": ["Beat expectations", "Margin expansion", "Operating growth"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.201073, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 74.8, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Earnings", "Healthcare", "Share Buyback", "Split", "Surgical Robotics"], "evidence_basis": "", "score_included": true}, {"title": "The Galien Foundation Announces 2026 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\"", "summary": "A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo \"We are proud to recog", "url": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "52566e8435df13cf73fa9717888920ac2672a0bb56e76834a3490f915476fab8", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.497, "provider_directional_mass": 0.156, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 62, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.118983, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 81.2, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Fda Approval", "Pharmaceuticals", "Rare Diseases"], "evidence_basis": "", "score_included": true}, {"title": "What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders", "summary": "In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these developments highlight Johnson & Johnson's effort to reposition around higher-growth innovative medicines and me", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-ottava-fda-002047054.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-ottava-fda-002047054.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T00:20:47+00:00", "published_display": "11 Aug 2026 00:20", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "0044943f6429ffb0ca0d8fc9815e2d21211deaa6908ab3f9bd3bcb689cacfb9b", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.619, "provider_directional_mass": 0.175, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.425, "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.119922, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 69.4, "age_days": 2.6, "influence_label": "Low", "duplicate_count": 3, "topics": ["Fda Approval", "Litigation", "Medtech", "Oncology", "Revenue Growth", "Robotics"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?", "summary": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:36:57+00:00", "published_display": "10 Aug 2026 22:36", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "99a501eedeb3958ebe6a4d1351adb2e9a43c8bc2f34e87f9aa19ae7d64103286", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.785, "provider_directional_mass": 0.197, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.211, "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Guidance raised", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.199403, "evidence_share": 3.8, "evidence_share_display": "3.8", "freshness_pct": 68.7, "age_days": 2.7, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Growth", "Earnings Per Share", "Guidance", "Healthcare", "Medical Devices"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?", "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 \u2060billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong ", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T20:49:59+00:00", "published_display": "10 Aug 2026 20:49", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "d3ab2b7502c0abaac5cde1db78f3d61c3eea5a4004021eb3d7b5a05c0c8bffc5", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.786, "provider_directional_mass": 0.209, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.213, "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Strong Demand"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.197611, "evidence_share": 3.8, "evidence_share_display": "3.8", "freshness_pct": 68.0, "age_days": 2.8, "influence_label": "Low", "duplicate_count": 3, "topics": ["Diagnostics", "Earnings", "Earnings Growth", "Earnings Per Share", "Guidance", "Healthcare"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY", "summary": "During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the\u2026 Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these\u2026 I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a", "url": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:07:30+00:00", "published_display": "10 Aug 2026 18:07", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "8b0ace502be00ea4bc72828a6487f37dc7a95891208f25bb0d9a938c27f240fa", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.614, "provider_directional_mass": 0.214, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.95, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.089167, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 67.0, "age_days": 2.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "Fourth Quarter", "Healthcare", "M A"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance", "summary": "On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC's Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That's the big medical technology and supply play... That was formerly known as Becton, Dickson. This was the first full quarter after they split off their biosciences and diagnostics business, something we loved. They posted a 9-cent earnings beat off a $3.14 basis, higher-than-expected revenue, up 5.4% year-over-year. They also said their full-year revenue growth would be toward ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-sees-cheap-valuation-175313326.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-sees-cheap-valuation-175313326.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:53:13+00:00", "published_display": "10 Aug 2026 17:53", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "41c92cab4ed8e228545e082a0cd11628d94fc82e3e905d6caa827d052eed5bbd", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.84, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 91, "tone_signals": ["Beat expectations", "Guidance raised", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.235685, "evidence_share": 4.5, "evidence_share_display": "4.5", "freshness_pct": 66.9, "age_days": 2.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Earnings", "Earnings Per Share", "Fourth Quarter", "Free Cash Flow", "Guidance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "The \u201cSet It & Forget It\u201d Stocks I\u2019d Want to Own", "summary": "Quick Read SBAC tops the group at a 2.58% yield, while JNJ's 64-year dividend streak and AAA credit rating make both core income holdings. $100,000 split equally across all four stocks generates $2,304 in annual passive income, a 2.30% blended yield that compounds as each company raises payouts. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Passive income is the ballast that keeps a portfolio steady when paychecks get interrupted. Layoffs, medical bills, or a ma", "url": "https://finance.yahoo.com/markets/stocks/articles/set-forget-stocks-d-want-170014127.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/set-forget-stocks-d-want-170014127.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:00:14+00:00", "published_display": "10 Aug 2026 17:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "fa2bd74532ed63d180f4856953233c32ba3d6ad211755a68e7ab0a48f37e6d21", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.67, "provider_directional_mass": 0.16, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.389, "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Improving financial comparison", "Operational disruption"], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.167246, "evidence_share": 3.2, "evidence_share_display": "3.2", "freshness_pct": 74.8, "age_days": 2.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Credit Rating", "Dividends", "Free Cash Flow", "Healthcare"], "evidence_basis": "", "score_included": true}, {"title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "summary": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "source_link": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:42:00+00:00", "published_display": "10 Aug 2026 14:42", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "927f9ccad8a76401c0a14360109ddd557d24db34a3e730f18f16ee3d81dbc74b", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.662, "provider_directional_mass": 0.152, "relevance_score": 0.45, "entity_mapped": true, "sentiment_conflict": 0.145, "sentiment": "positive", "sentiment_pct": 79, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.114905, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 65.7, "age_days": 3.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Fda Approval", "Guidance", "Medical Instruments", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight", "summary": "The major depressive disorder market is experiencing a significant transformation as rapid-acting therapies with novel mechanisms of action complement conventional SSRIs and SNRIs. Recent treatment approvals have broadened therapeutic choices for patients with TRD and those who do not achieve adequate benefit from standard antidepressants. Meanwhile, pipeline candidates such as Seltorexant (Johnson & Johnson), Azetukalner (Xenon Pharmaceuticals), Itruvone (VistaGen), and others are advancing through clinical development to deliver improved efficacy, faster symptom relief, and better tolerabili", "url": "https://finance.yahoo.com/healthcare/articles/major-depressive-disorder-market-predicted-143100937.html", "source_link": "https://finance.yahoo.com/healthcare/articles/major-depressive-disorder-market-predicted-143100937.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:31:00+00:00", "published_display": "10 Aug 2026 14:31", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "27e2e718d6ccf16a48518bb82959e60904fcb9b060b06418209e280cce0f1ec6", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.625, "provider_directional_mass": 0.2647, "relevance_score": 0.519615, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Guidance raised"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.126793, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 74.0, "age_days": 3.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Antidepressants", "Clinical Trials", "Major Depressive Disorder", "Market Research Reports", "Pharmaceuticals"], "evidence_basis": "", "score_included": true}, {"title": "Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava\u2019s FDA Approval?", "summary": "Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differ", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:42:42+00:00", "published_display": "10 Aug 2026 12:42", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "1f3a1d2d0e41f5a6089112952037dac0c453a7c78b4d75fbfa04ceabaf7c7c68", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.451, "provider_directional_mass": 0.157, "relevance_score": 0.355761, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.0453, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 64.9, "age_days": 3.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Fda Approval", "Financial Results", "Healthcare", "Medtech", "Robotic Surgery"], "evidence_basis": "", "score_included": true}, {"title": "3 Beaten-Down Healthcare Stocks to Buy in August", "summary": "Quick Read LLY grew Q1 revenue 56% and won FDA approval for the first oral GLP-1 pill, yet still trades 6% off its 52-week high. Healthcare has trailed SPY's 8% YTD gain, but JNJ's 64-year dividend streak and 20x forward P/E keep it compelling for value investors. ABBV's Skyrizi and Rinvoq surged 31% and 23%, more than offsetting Humira's decline while supporting a 53-year consecutive dividend increase streak. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Year t", "url": "https://finance.yahoo.com/healthcare/articles/3-beaten-down-healthcare-stocks-120055911.html", "source_link": "https://finance.yahoo.com/healthcare/articles/3-beaten-down-healthcare-stocks-120055911.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:00:55+00:00", "published_display": "10 Aug 2026 12:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "eb1d1dacdb98c9ac0b650a3166e05d86c128617b4a49541af443a5f0965c6eb6", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.774, "provider_directional_mass": 0.186, "relevance_score": 0.402489, "entity_mapped": true, "sentiment_conflict": 0.315, "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Guidance raised", "Improving financial comparison", "Deteriorating financial comparison", "Contract or approval won"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.1239, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 64.7, "age_days": 3.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Dividends", "Earnings", "Fda Approval", "Healthcare", "Pharma"], "evidence_basis": "", "score_included": true}, {"title": "ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers", "summary": "Agreement supports ACCESS-affiliated ASCs in adopting the CARTO\u2122 System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers (ASC) across the United States. The agreement encompasses an integrated portfolio of three-dim", "url": "https://finance.yahoo.com/healthcare/articles/access-announces-multi-strategic-agreement-110000847.html", "source_link": "https://finance.yahoo.com/healthcare/articles/access-announces-multi-strategic-agreement-110000847.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T11:00:00+00:00", "published_display": "10 Aug 2026 11:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "48680649f61aa07094b84be45dde7fdb2ff4f4dd97614fcc65b1e87afbf88447", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.578, "provider_directional_mass": 0.2477, "relevance_score": 0.318195, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 71, "tone_signals": ["Operating growth"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.02485, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 33.1, "age_days": 3.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Ambulatory Surgery Centers", "Cardiovascular Care", "Electrophysiology"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson (JNJ) Stock Analysis: Evaluating Its 5.11% Potential Upside", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+%28JNJ%29+Stock+Analysis%3A+Evaluating+Its+5.11%25+Potential+Upside%22+%22DirectorsTalk+Interviews%22", "source_link_is_lookup": true, "source_name": "DirectorsTalk Interviews", "published_at": "2026-08-10T09:16:36+00:00", "published_display": "10 Aug 2026 09:16", "provider": "archive", "providers": ["archive"], "source_names": ["DirectorsTalk Interviews"], "source_kind": "publisher", "story_key": "d4e340cd0fb056d1124293ab429cff2ea30836d91e9d429c70cfff1ef5108acb", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023958, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 32.3, "age_days": 3.3, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.", "summary": "Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we like better than Johnson & Johnson \u203a It's certainly not the market's most exciting stock, and not its highest-yielding one either. If you want reliable dividend growth, though, you'd be hard-pressed to find a better option than drugmaker Johnson & Johnson(NYSE: JNJ). In fact, after 64 straight years of annual dividend increases --", "url": "https://www.nasdaq.com/articles/johnson-johnson-has-increased-its-dividend-64-consecutive-years-heres-how-much-10000", "source_link": "https://www.nasdaq.com/articles/johnson-johnson-has-increased-its-dividend-64-consecutive-years-heres-how-much-10000", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-09T13:35:00+00:00", "published_display": "09 Aug 2026 13:35", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["nasdaq.com"], "source_kind": "publisher", "story_key": "87a1fc6b527bdca11053464b79d729c447de8f314f33673826d4f20bc8906505", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.689, "provider_directional_mass": 0.14, "relevance_score": 0.9, "entity_mapped": true, "sentiment_conflict": 0.382, "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Improving financial comparison", "Capital returned"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.143065, "evidence_share": 2.7, "evidence_share_display": "2.7", "freshness_pct": 66.8, "age_days": 4.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Acquisitions", "Dividends", "Markets", "Oncology", "Pharmaceuticals"], "evidence_basis": "", "score_included": true}, {"title": "How Much Do You Need Invested to Out-Earn the Average Social Security Check With Dividends?", "summary": "Quick Read Replacing the $24,000 average Social Security check with dividends requires $685,000 at a 3.5% yield, $400,000 at 6%, or $240,000 at a risky 10%. A 3.5% yield growing 8% annually doubles income in 9 years, while a flat 10% yield stagnates and often erodes principal over time. The 10-year Treasury at 4.6% generates $24,000 with roughly $518,000 invested, setting the real risk-adjusted benchmark any dividend strategy must beat. Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor ha", "url": "https://finance.yahoo.com/markets/stocks/articles/much-invested-earn-average-social-213708497.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/much-invested-earn-average-social-213708497.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T21:37:08+00:00", "published_display": "08 Aug 2026 21:37", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "5847ed6a35ca97276a2ed5ac5398ab7cef8a07dd63065eb0c26de9dd1f9426e0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.733, "provider_directional_mass": 0.111, "relevance_score": 0.402489, "entity_mapped": true, "sentiment_conflict": 0.544, "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Improving financial comparison", "Deteriorating financial comparison", "Capital returned"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.076194, "evidence_share": 1.5, "evidence_share_display": "1.5", "freshness_pct": 51.8, "age_days": 4.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Dividends", "Growth Rate", "Income", "Retirement", "Treasuries", "Yield"], "evidence_basis": "", "score_included": true}, {"title": "Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?", "summary": "Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic \u203a Medtronic(NYSE: MDT) and Intuitive Surgical(NASDAQ: ISRG), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there ", "url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "source_link": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-08T21:20:00+00:00", "published_display": "08 Aug 2026 21:20", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["nasdaq.com"], "source_kind": "publisher", "story_key": "cfa2e9eeef0f04003ff3ff3d17190b682d47e0feabacf8398b58a2ff1baa3870", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.761, "provider_directional_mass": 0.178, "relevance_score": 0.519615, "entity_mapped": true, "sentiment_conflict": 0.402, "sentiment": "positive", "sentiment_pct": 75, "tone_signals": ["Beat expectations", "Improving financial comparison", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.113668, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 51.7, "age_days": 4.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["Competition", "Dividends", "Earnings", "Earnings Growth", "Earnings Per Share", "Earnings Release"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Is Telling Investors to Accumulate SpaceX for the Long Term", "summary": "During CNBC's Mad Money episode aired on August 5, Jim Cramer addressed investor concerns surrounding Space Exploration Technologies Corp. (NASDAQ:SPCX) and its immense capital requirements. Explaining why he remains bullish on SpaceX's long-term trajectory despite the massive expenditures involved, Cramer stated: I want to take this moment to explain why the stock might be valuable years down the road. Again, with the caveat that I don't know how many years or even which road, but you know what? It doesn't matter. I'm not being facetious here. This is Elon Musk we're talking about, quite poss", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-telling-investors-accumulate-200218837.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-telling-investors-accumulate-200218837.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T20:02:18+00:00", "published_display": "08 Aug 2026 20:02", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "06c87b0a56e291a498b9127c0eaac3c343a4eca2aa148653653331a588fb6b76", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.724, "provider_directional_mass": 0.1618, "relevance_score": 0.519615, "entity_mapped": true, "sentiment_conflict": 0.188, "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Positive valuation view", "Negative valuation view"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023919, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 18.9, "age_days": 4.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Investing", "Launch Systems", "Satellites", "Space", "Telecom"], "evidence_basis": "", "score_included": true}, {"title": "SA Asks: What's the outlook for Big Pharma M&A?", "summary": "[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth", "url": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T19:28:35+00:00", "published_display": "08 Aug 2026 19:28", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "fd6f6ddc120c4d3f8b5e3d484fa6bed2d394475902a0ec5eeeefda565db16bfa", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.614, "provider_directional_mass": 0.0989, "relevance_score": 0.201249, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 34, "tone_signals": ["Operating deterioration"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.058471, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 62.0, "age_days": 4.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biotech", "Fda Approval", "M&a", "M A", "Oncology", "Pharma"], "evidence_basis": "", "score_included": true}, {"title": "Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech", "summary": "Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 stocks we like better than Intuitive Surgical \u203a Intuitive Surgical(NASDAQ: ISRG) can be hard to own because the stock is prone to deep drawdowns. It is in a drawdown right now, with the stock down roughly 40% from its early 2025 high. Even after that drop, the price-to-earnings ratio remains lofty at 42x. Th", "url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "source_link": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-08T16:35:00+00:00", "published_display": "08 Aug 2026 16:35", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["nasdaq.com"], "source_kind": "publisher", "story_key": "0228fda7a01299989d2cdb3dc45402850ea86f8309b6e3713d2645b01b96fb53", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.727, "provider_directional_mass": 0.114, "relevance_score": 0.519615, "entity_mapped": true, "sentiment_conflict": 0.133, "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.111084, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 50.3, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["Competition", "Growth Investing", "Growth Stocks", "Healthcare", "Markets", "Recurring Revenue"], "evidence_basis": "", "score_included": true}, {"title": "iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?", "summary": "Key Points iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total return of 80.2% but a significantly deeper maximum drawdown. iShares Global Healthcare ETF provides international exposure to major pharmaceutical and healthcare companies, while the State Street fund uses an equal-weighted U.S. biotech strategy.10 stocks we like better than iShares Trust - iShares Global Healthcare ETF \u203a Investors choosing between iShares Glob", "url": "https://www.nasdaq.com/articles/ishares-global-healthcare-etf-vs-state-street-spdr-biotech-etf-which-healthcare-focused", "source_link": "https://www.nasdaq.com/articles/ishares-global-healthcare-etf-vs-state-street-spdr-biotech-etf-which-healthcare-focused", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-08T16:22:01+00:00", "published_display": "08 Aug 2026 16:22", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["nasdaq.com"], "source_kind": "publisher", "story_key": "66bc9b27ccbb61d1e2fd7fa70dd3e3d116e4cd7280df9d3632b2d80b06244c67", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.604, "provider_directional_mass": 0.155, "relevance_score": 0.318195, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 38, "tone_signals": ["Deteriorating financial comparison"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.052402, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 50.2, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["Biotech", "Dividends", "Etfs", "Healthcare", "Markets", "Pharmaceutical"], "evidence_basis": "", "score_included": true}, {"title": "Why PG, JNJ, and KO Could Surprise Investors Next Year", "summary": "Quick Read PG and JNJ target $180 and $300 respectively, with JNJ's oncology pipeline posting drug growth up to 83% in Q1. KO's FIFA World Cup 2026 activation across 180+ markets, paired with Zero Sugar volume up 16%, builds the case for $100. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Defensive blue chips rarely dominate headlines, but heading into 2027, three of the market's most reliable dividend payers stand out as durable compounders.Kenneth C. Zirkel / ", "url": "https://finance.yahoo.com/markets/stocks/articles/why-pg-jnj-ko-could-160053178.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/why-pg-jnj-ko-could-160053178.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T16:00:53+00:00", "published_display": "08 Aug 2026 16:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "ecf7d9e29561fd314100ab6640e0663aff3e88d426fabb811d4d58b6388ba130", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.784, "provider_directional_mass": 0.185, "relevance_score": 0.649521, "entity_mapped": true, "sentiment_conflict": 0.037, "sentiment": "positive", "sentiment_pct": 88, "tone_signals": ["Beat expectations", "Guidance raised", "Raised Guidance", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.142925, "evidence_share": 2.7, "evidence_share_display": "2.7", "freshness_pct": 50.1, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Consumer Staples", "Dividends", "Earnings", "Free Cash Flow", "Healthcare", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?", "summary": "Key Points Vanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF. State Street Health Care Select Sector SPDR ETF is slightly more cost-effective with an expense ratio of 0.08% versus 0.09% for the Vanguard fund. While Vanguard Health Care ETF has higher 1-year total returns, State Street Health Care Select Sector SPDR ETF has achieved higher overall growth for a $1,000 investment over the last five years.10 stocks we like better than Vanguard World Fund - Vanguard Health Care ETF \u203a The State ", "url": "https://www.nasdaq.com/articles/vanguard-health-care-etf-vs-state-street-xlv-which-etf-better-buy-investors-2026", "source_link": "https://www.nasdaq.com/articles/vanguard-health-care-etf-vs-state-street-xlv-which-etf-better-buy-investors-2026", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-08T15:53:01+00:00", "published_display": "08 Aug 2026 15:53", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["nasdaq.com"], "source_kind": "publisher", "story_key": "211246726cdcdbc61ab079941eae296e278be04cb80f1559937bb02c0f85dea5", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.449, "provider_directional_mass": 0.1321, "relevance_score": 0.402489, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.008756, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 17.8, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 1, "topics": ["Dividends", "ETF", "Healthcare", "Markets", "Share Price"], "evidence_basis": "", "score_included": true}, {"title": "The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?", "summary": "Quick Read A blended portfolio made up of two-thirds dividend growth at 3.5% and one-third income at 6% generates $56,000 annually from $1.25M, beating the 4% rule without touching principal. Dividend growers like JNJ and AMGN raising payouts at 6% annually double retirement income in roughly 12 years without adding new capital. mREITs and BDCs yielding 10%+ risk NAV erosion and recession-driven distribution cuts, effectively turning a $1.25M nest egg into a self-liquidating annuity. Many financial professionals are salespeople paid on what they push, not whether you end up wealthier. A fiduci", "url": "https://finance.yahoo.com/markets/stocks/articles/4-rule-vs-dividend-paycheck-230556163.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/4-rule-vs-dividend-paycheck-230556163.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T23:05:56+00:00", "published_display": "07 Aug 2026 23:05", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "9f5e2f491b020478ec7a53b7e0f8c9064061810efcd3e5529e8267390a0108d0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.596, "provider_directional_mass": 0.15, "relevance_score": 0.402489, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Operating growth"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.053357, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 45.5, "age_days": 5.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Dividends", "Income Strategy", "Retirement", "Wealth Management", "Yield Curve"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company's talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to o", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-reaches-5-191035095.html", "source_link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-reaches-5-191035095.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:10:35+00:00", "published_display": "07 Aug 2026 19:10", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "cf4c1cfdc2afd2eff01baf4bd41376d7649feff3cae6f90af7b97c54f9e6fd47", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.495, "provider_directional_mass": 0.1371, "relevance_score": 0.397746, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 59, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.054244, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 56.0, "age_days": 5.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Balance Sheet", "Consumer Health", "Legal Issues", "Settlement"], "evidence_basis": "", "score_included": true}, {"title": "Johnson & Johnson Dividend Stock Analysis: 64 Years of Increases and Current Valuation - News and Statistics", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+Dividend+Stock+Analysis%3A+64+Years+of+Increases+and+Current+Valuation+-+News+and+Statistics%22+%22IndexBox%22", "source_link_is_lookup": true, "source_name": "IndexBox", "published_at": "2026-08-05T09:08:25.492959+00:00", "published_display": "05 Aug 2026 09:08", "provider": "archive", "providers": ["archive"], "source_names": ["IndexBox"], "source_kind": "publisher", "story_key": "c048df812281633b5bedc00f663f2dc061658430975b6385a1aba621fe5b516d", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024851, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 31.8, "age_days": 8.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson stock holds just above $250.92 support as conflicting signals persist: weekly analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPbGhXUHpPWk1pNUNyWVduTy1zZEZRdEhNZTZnbTVkWTNvZXdtZjZSVll0cXpKUktZcTBtTnNmUVNYQ3QzOEdYYmF1dnBRZlo5eGY2cmUxckFsT1ZSdG1NVVVLTFVSV0JZOGJxQVZUYy1maWFycGVrX1FOUy1sbXg3VkFpa2htUl9VZjVrTE5FaFk?oc=5", "source_link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPbGhXUHpPWk1pNUNyWVduTy1zZEZRdEhNZTZnbTVkWTNvZXdtZjZSVll0cXpKUktZcTBtTnNmUVNYQ3QzOEdYYmF1dnBRZlo5eGY2cmUxckFsT1ZSdG1NVVVLTFVSV0JZOGJxQVZUYy1maWFycGVrX1FOUy1sbXg3VkFpa2htUl9VZjVrTE5FaFk?oc=5", "source_link_is_lookup": false, "source_name": "Traders Union", "published_at": "2026-08-04T14:13:36+00:00", "published_display": "04 Aug 2026 14:13", "provider": "archive", "providers": ["archive", "google_news"], "source_names": ["Traders Union"], "source_kind": "publisher", "story_key": "53e646b27086435f8f5dff644d0b0bb659b1756e34b53d82caace81b90bc6c93", "target_scope": "", "durable_archive": false, "archive_provider": "google_news", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00232, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 4.3, "age_days": 9.1, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson (JNJ) Stock Analysis: Here\u2019s Why Investors Are Eyeing A 5.73% Upside", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+%28JNJ%29+Stock+Analysis%3A+Here%E2%80%99s+Why+Investors+Are+Eyeing+A+5.73%25+Upside%22+%22DirectorsTalk+Interviews%22", "source_link_is_lookup": true, "source_name": "DirectorsTalk Interviews", "published_at": "2026-08-03T09:06:47+00:00", "published_display": "03 Aug 2026 09:06", "provider": "archive", "providers": ["archive"], "source_names": ["DirectorsTalk Interviews"], "source_kind": "publisher", "story_key": "4680d4d7d7786a92fb4706c54518f7083e3272f534055ddec4427ff7511a2403", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002113, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 2.8, "age_days": 10.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson makes $465 million equity investment in Sail Biomedicines", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+makes+%24465+million+equity+investment+in+Sail+Biomedicines%22+%22Bitget%22", "source_link_is_lookup": true, "source_name": "Bitget", "published_at": "2026-08-03T03:58:25.366157+00:00", "published_display": "03 Aug 2026 03:58", "provider": "archive", "providers": ["archive"], "source_names": ["Bitget"], "source_kind": "publisher", "story_key": "87235b92fc2add632ae552a296c6336e2a78c1235b29eebb35ea8224ac1529ed", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001415, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 2.6, "age_days": 10.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson reaches $5.5 billion baby powder settlement", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+reaches+%245.5+billion+baby+powder+settlement%22+%22Reuters%22", "source_link_is_lookup": true, "source_name": "Reuters", "published_at": "2026-07-31T11:58:24.075473+00:00", "published_display": "31 Jul 2026 11:58", "provider": "archive", "providers": ["archive"], "source_names": ["Reuters"], "source_kind": "editorial_wire", "story_key": "d7be5479565a7c7238d06476a536c9db5045cbd2ee28cb264dba04716e7fd744", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000936, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 1.0, "age_days": 13.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+proposes+%245.5B+settlement+to+resolve+remaining+talc+litigation%22+%22Proactive+financial+news%22", "source_link_is_lookup": true, "source_name": "Proactive financial news", "published_at": "2026-07-29T10:28:25.299097+00:00", "published_display": "29 Jul 2026 10:28", "provider": "archive", "providers": ["archive"], "source_names": ["Proactive financial news"], "source_kind": "publisher", "story_key": "ff8fe081bc27c4b7925d111fe4ec535e50b26b376fb2b8b965f8fb7982d60339", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000275, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.5, "age_days": 15.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson stock trades steadily as diversified healthcare earnings support valuation", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+stock+trades+steadily+as+diversified+healthcare+earnings+support+valuation%22+%22AD+HOC+NEWS%22", "source_link_is_lookup": true, "source_name": "AD HOC NEWS", "published_at": "2026-07-27T03:58:25.135750+00:00", "published_display": "27 Jul 2026 03:58", "provider": "archive", "providers": ["archive"], "source_names": ["AD HOC NEWS"], "source_kind": "publisher", "story_key": "ee26d912f4bc7e6a8cbe351f7fe72f8e11eacdb4e97a4571679b93d7cc1d38c5", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007291, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 8.9, "age_days": 17.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Why+Johnson+%26+Johnson+Is+Sending+Intuitive+Surgical+%28ISRG%29+Stock+Down+Today%22+%22Barchart.com%22", "source_link_is_lookup": true, "source_name": "Barchart.com", "published_at": "2026-07-23T22:07:57.580136+00:00", "published_display": "23 Jul 2026 22:07", "provider": "archive", "providers": ["archive"], "source_names": ["Barchart.com"], "source_kind": "publisher", "story_key": "8fceedd8d11632d5486ae0dbcc2ed3bb5a9bd074341a5616a0f678a5cb28da06", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4.1e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 20.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Unusual Put Option Activity in Johnson & Johnson After JNJ Stock's Recent Runup", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Unusual+Put+Option+Activity+in+Johnson+%26+Johnson+After+JNJ+Stock%27s+Recent+Runup%22+%22Barchart.com%22", "source_link_is_lookup": true, "source_name": "Barchart.com", "published_at": "2026-07-21T09:28:23.758629+00:00", "published_display": "21 Jul 2026 09:28", "provider": "archive", "providers": ["archive"], "source_names": ["Barchart.com"], "source_kind": "publisher", "story_key": "f44f445a715601efdd6aa44372c756d77a10296e982da167156d7bf3bfd758e3", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1.7e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 23.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Johnson & Johnson analyst consensus stays supportive, shares trade steadily on the NYSE", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Johnson+%26+Johnson+analyst+consensus+stays+supportive%2C+shares+trade+steadily+on+the+NYSE%22+%22ad-hoc-news.de%22", "source_link_is_lookup": true, "source_name": "ad-hoc-news.de", "published_at": "2026-07-20T03:58:23.724338+00:00", "published_display": "20 Jul 2026 03:58", "provider": "archive", "providers": ["archive"], "source_names": ["ad-hoc-news.de"], "source_kind": "publisher", "story_key": "307190ffe040c56c6233674a7261820b5757bc61059545cdc7ed21f9b9d58f61", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00023, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.3, "age_days": 24.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Dividend+King+vs.+Growth+Giant%3A+Johnson+%26+Johnson+Takes+on+Eli+Lilly%22+%22AOL.com%22", "source_link_is_lookup": true, "source_name": "AOL.com", "published_at": "2026-07-17T09:28:24.016688+00:00", "published_display": "17 Jul 2026 09:28", "provider": "archive", "providers": ["archive"], "source_names": ["AOL.com"], "source_kind": "publisher", "story_key": "562b87079da6f64c9265d473a6bd86b59aaa6da5cceec0efdd01a25c5251cb66", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001788, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 2.3, "age_days": 27.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "industry": [], "sector": []}, "total_fetched": 52, "total_unique": 52, "total_relevant": 52, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 43}, "raw_articles": 78, "unique_stories": 52, "duplicates_removed": 26, "relevant_stories": 52, "matched_archive_stories": 52, "current_evidence": 52, "direct_evidence": 52, "eodhd_articles": 40, "archive_articles": 12, "eodhd": {"configured": true, "status": "healthy", "calls_used": 395, "call_budget": 500, "budget_used_pct": 79.0, "requests_made": 79, "last_success_at": "2026-08-13T15:16:12.464676+00:00", "newest_seen_at": "2026-08-13T15:15:00+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3162, "unmapped_mentions": 1986}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-13T12:40:39.410907+00:00", "durable_newest_article_at": "2026-08-12T21:13:16+00:00", "durable_story_count": 25}, "sentiment_summary": {"positive": 36, "negative": 2, "neutral": 14, "score": 71, "raw_score": 74, "total": 52, "evidence_count": 52, "effective_articles": 31.33, "information_mass": 5.218, "direct_story_count": 52, "direct_source_count": 13, "industry_story_count": 0, "sector_story_count": 0, "story_count": 52, "source_count": 13, "source_concentration": 0.7807, "direct_share": 100, "dispersion": 12, "confidence": 70, "evidence_status": "measured", "score_version": "evidence-v7", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-13T12:00:00+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 73, "events": [{"event": "earnings", "label": "Earnings", "weight": 11.15, "count": 20}, {"event": "general", "label": "Market update", "weight": 8.1, "count": 13}, {"event": "capital_return", "label": "Capital return", "weight": 3.45, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 2.25, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.75, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}], "positive_events": 36, "negative_events": 2, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 43}, "raw_articles": 78, "unique_stories": 52, "duplicates_removed": 26, "relevant_stories": 52, "matched_archive_stories": 52, "current_evidence": 52, "direct_evidence": 52, "eodhd_articles": 40, "archive_articles": 12, "eodhd": {"configured": true, "status": "healthy", "calls_used": 395, "call_budget": 500, "budget_used_pct": 79.0, "requests_made": 79, "last_success_at": "2026-08-13T15:16:12.464676+00:00", "newest_seen_at": "2026-08-13T15:15:00+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3162, "unmapped_mentions": 1986}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-13T12:40:39.410907+00:00", "durable_newest_article_at": "2026-08-12T21:13:16+00:00", "durable_story_count": 25}}, "market_context": {"has_market_context": true, "latest_close": 1640.0, "latest_week": "2026-08-07", "one_week_move": -34.4, "four_week_move": 0.0, "twelve_week_move": 0.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.057179, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -3.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 9.1153, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-34.4% over one week, +0.0% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 80, "badges": ["Sentiment confirms active trend"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": [], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 32}, {"label": "nasdaq.com", "count": 6}, {"label": "seekingalpha.com", "count": 2}, {"label": "DirectorsTalk Interviews", "count": 2}, {"label": "Barchart.com", "count": 2}, {"label": "IndexBox", "count": 1}, {"label": "Traders Union", "count": 1}, {"label": "Bitget", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 20}, {"label": "Market update", "count": 13}, {"label": "Capital return", "count": 6}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "71/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "70/100", "tone": "positive", "text": "31.33 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "73/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "12/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-34.4% over one week, +0.0% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results"}], "updated_at": "2026-08-13T12:40:39.410907+00:00", "detail_intelligence": {"headline": "Constructive news tone", "summary": "The score uses 52 current company stories from 13 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 71, "display": "71", "tone": "positive", "note": "Constructive news tone"}, {"label": "Confidence", "value": 70, "display": "70", "tone": "positive", "note": "solid confidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "52 company stories"}, {"label": "Story agreement", "value": 88, "display": "88", "tone": "positive", "note": "12/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 100, "note": "5.26 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "13 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 68, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 88, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 22, "note": "less reliance on one publisher"}], "freshness": 68, "source_independence": 22, "timeline": [{"date": "2026-07-15", "label": "15 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-16", "label": "16 Jul", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-17", "label": "17 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-07-18", "label": "18 Jul", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-19", "label": "19 Jul", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-20", "label": "20 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-07-21", "label": "21 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-07-22", "label": "22 Jul", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-23", "label": "23 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 2, "score": 54, "tone": "neutral", "x": 642.1, "y": 127.7, "volume_height": 9.5, "volume_y": 256.5}, {"date": "2026-08-04", "label": "04 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-08-05", "label": "05 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 2, "score": 63, "tone": "positive", "x": 768.5, "y": 111.3, "volume_height": 9.5, "volume_y": 256.5}, {"date": "2026-08-08", "label": "08 Aug", "count": 8, "score": 70, "tone": "positive", "x": 800.1, "y": 98.6, "volume_height": 37.8, "volume_y": 228.2}, {"date": "2026-08-09", "label": "09 Aug", "count": 1, "score": 68, "tone": "positive", "x": 831.7, "y": 102.2, "volume_height": 4.7, "volume_y": 261.3}, {"date": "2026-08-10", "label": "10 Aug", "count": 11, "score": 77, "tone": "positive", "x": 863.2, "y": 85.9, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 9, "score": 79, "tone": "positive", "x": 894.8, "y": 82.2, "volume_height": 42.5, "volume_y": 223.5}, {"date": "2026-08-12", "label": "12 Aug", "count": 9, "score": 72, "tone": "positive", "x": 926.4, "y": 95.0, "volume_height": 42.5, "volume_y": 223.5}, {"date": "2026-08-13", "label": "13 Aug", "count": 1, "score": 63, "tone": "positive", "x": 958.0, "y": 111.3, "volume_height": 4.7, "volume_y": 261.3}], "timeline_points": "105.2,135.0 199.9,135.0 231.5,135.0 294.7,135.0 421.0,135.0 484.2,135.0 547.4,135.0 642.1,127.7 673.7,135.0 705.3,135.0 768.5,111.3 800.1,98.6 831.7,102.2 863.2,85.9 894.8,82.2 926.4,95.0 958.0,111.3", "timeline_has_signal": true, "timeline_start": "15 Jul", "timeline_mid": "30 Jul", "timeline_end": "13 Aug", "momentum": {"label": "Improving", "tone": "positive", "recent_score": 76, "prior_score": 69, "delta": 7, "recent_count": 26, "prior_count": 15, "volume_delta": 11, "reliable": true, "reliability_note": "Confirmed by at least two stories in both periods"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 5, "share": 10}, {"label": "1 to 3 days", "count": 21, "share": 40}, {"label": "4 to 7 days", "count": 15, "share": 29}, {"label": "8 to 14 days", "count": 5, "share": 10}, {"label": "15 to 21 days", "count": 3, "share": 6}, {"label": "22 to 30 days", "count": 3, "share": 6}], "source_profile": [{"label": "finance.yahoo.com", "count": 32, "share": 62, "score": 76, "tone": "positive"}, {"label": "nasdaq.com", "count": 6, "share": 12, "score": 66, "tone": "positive"}, {"label": "seekingalpha.com", "count": 2, "share": 4, "score": 39, "tone": "negative"}, {"label": "DirectorsTalk Interviews", "count": 2, "share": 4, "score": 57, "tone": "neutral"}, {"label": "Barchart.com", "count": 2, "share": 4, "score": 50, "tone": "neutral"}, {"label": "IndexBox", "count": 1, "share": 2, "score": 50, "tone": "neutral"}, {"label": "Traders Union", "count": 1, "share": 2, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 20, "share": 38, "score": 79, "tone": "positive"}, {"label": "Market update", "count": 13, "share": 25, "score": 57, "tone": "neutral"}, {"label": "Capital return", "count": 6, "share": 12, "score": 70, "tone": "positive"}, {"label": "Analyst action", "count": 4, "share": 8, "score": 72, "tone": "positive"}, {"label": "Deals and strategy", "count": 3, "share": 6, "score": 60, "tone": "positive"}, {"label": "Regulatory and legal", "count": 3, "share": 6, "score": 60, "tone": "positive"}, {"label": "Balance sheet", "count": 2, "share": 4, "score": 73, "tone": "positive"}], "topics": [{"label": "Earnings", "count": 15, "share": 29}, {"label": "Healthcare", "count": 13, "share": 25}, {"label": "Fda Approval", "count": 11, "share": 21}, {"label": "Dividends", "count": 10, "share": 19}, {"label": "Biotech", "count": 10, "share": 19}, {"label": "Balance Sheet", "count": 9, "share": 17}, {"label": "Guidance", "count": 6, "share": 12}, {"label": "Earnings Per Share", "count": 6, "share": 12}, {"label": "Revenue Growth", "count": 5, "share": 10}, {"label": "Price Target", "count": 5, "share": 10}], "supporting": [{"label": "Direct evidence", "text": "52 current stories are mapped specifically to DJNJ3."}, {"label": "Source breadth", "text": "The read spans 13 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 88/100."}], "tempering": [{"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results", "summary": "MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Ob", "url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "source_link": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T12:00:00+00:00", "published_display": "13 Aug 2026 12:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Dilution risk"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.122491, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 99.1, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Fda Approval", "Gene Therapy", "Net Income"], "evidence_basis": "", "score_included": true}, "article_count": 52, "updated_at": "2026-08-13T12:40:39.410907+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 185.7, "label": "13 Feb 2026", "close": 1746.96, "index": 100.0}, {"x": 78.4, "y": 200.1, "label": "20 Feb 2026", "close": 1663.97, "index": 95.2}, {"x": 114.9, "y": 200.1, "label": "27 Feb 2026", "close": 1664.0, "index": 95.3}, {"x": 151.3, "y": 200.1, "label": "06 Mar 2026", "close": 1664.0, "index": 95.3}, {"x": 187.7, "y": 200.1, "label": "13 Mar 2026", "close": 1664.0, "index": 95.3}, {"x": 224.2, "y": 200.1, "label": "20 Mar 2026", "close": 1664.0, "index": 95.3}, {"x": 260.6, "y": 200.1, "label": "27 Mar 2026", "close": 1664.0, "index": 95.3}, {"x": 297.0, "y": 200.1, "label": "03 Apr 2026", "close": 1664.0, "index": 95.3}, {"x": 333.5, "y": 200.1, "label": "10 Apr 2026", "close": 1664.0, "index": 95.3}, {"x": 369.9, "y": 200.1, "label": "17 Apr 2026", "close": 1664.0, "index": 95.3}, {"x": 406.3, "y": 204.2, "label": "24 Apr 2026", "close": 1640.0, "index": 93.9}, {"x": 442.8, "y": 204.2, "label": "01 May 2026", "close": 1640.0, "index": 93.9}, {"x": 479.2, "y": 204.2, "label": "08 May 2026", "close": 1640.0, "index": 93.9}, {"x": 515.6, "y": 204.2, "label": "15 May 2026", "close": 1640.0, "index": 93.9}, {"x": 552.0, "y": 204.2, "label": "22 May 2026", "close": 1640.0, "index": 93.9}, {"x": 588.5, "y": 204.2, "label": "29 May 2026", "close": 1640.0, "index": 93.9}, {"x": 624.9, "y": 204.2, "label": "05 Jun 2026", "close": 1640.0, "index": 93.9}, {"x": 661.3, "y": 204.2, "label": "12 Jun 2026", "close": 1640.0, "index": 93.9}, {"x": 697.8, "y": 204.2, "label": "19 Jun 2026", "close": 1640.0, "index": 93.9}, {"x": 734.2, "y": 204.2, "label": "26 Jun 2026", "close": 1640.0, "index": 93.9}, {"x": 770.6, "y": 204.2, "label": "03 Jul 2026", "close": 1640.0, "index": 93.9}, {"x": 807.1, "y": 204.2, "label": "10 Jul 2026", "close": 1640.0, "index": 93.9}, {"x": 843.5, "y": 204.2, "label": "17 Jul 2026", "close": 1640.0, "index": 93.9}, {"x": 879.9, "y": 204.2, "label": "24 Jul 2026", "close": 1640.0, "index": 93.9}, {"x": 916.4, "y": 55.8, "label": "31 Jul 2026", "close": 2500.0, "index": 143.1}, {"x": 952.8, "y": 204.2, "label": "07 Aug 2026", "close": 1640.0, "index": 93.9}], "sentiment_points": [{"at": "2026-02-27T23:59:59.999Z", "date": "2026-02-27", "label": "27 Feb 2026", "score": 51, "tone": "neutral", "raw_score": 55, "confidence": 29, "stories": 3, "close": 1664.0, "price_change": 0.0, "x": 120.1, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-03-06T23:59:59.999Z", "date": "2026-03-06", "label": "06 Mar 2026", "score": 50, "tone": "neutral", "raw_score": 56, "confidence": 20, "stories": 3, "close": 1664.0, "price_change": 0.0, "x": 156.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-03-13T23:59:59.999Z", "date": "2026-03-13", "label": "13 Mar 2026", "score": 50, "tone": "neutral", "raw_score": 55, "confidence": 17, "stories": 3, "close": 1664.0, "price_change": 0.0, "x": 192.9, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-03-20T23:59:59.999Z", "date": "2026-03-20", "label": "20 Mar 2026", "score": 50, "tone": "neutral", "raw_score": 54, "confidence": 15, "stories": 3, "close": 1664.0, "price_change": 0.0, "x": 229.4, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-03-27T23:59:59.999Z", "date": "2026-03-27", "label": "27 Mar 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 15, "stories": 2, "close": 1664.0, "price_change": 0.0, "x": 265.8, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-04-24T23:59:59.999Z", "date": "2026-04-24", "label": "24 Apr 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 18, "stories": 1, "close": 1640.0, "price_change": -1.4, "x": 411.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-01T23:59:59.999Z", "date": "2026-05-01", "label": "01 May 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 14, "stories": 1, "close": 1640.0, "price_change": 0.0, "x": 448.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-05-08T23:59:59.999Z", "date": "2026-05-08", "label": "08 May 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 14, "stories": 1, "close": 1640.0, "price_change": 0.0, "x": 484.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-15T23:59:59.999Z", "date": "2026-05-15", "label": "15 May 2026", "score": 50, "tone": "neutral", "raw_score": 57, "confidence": 20, "stories": 2, "close": 1640.0, "price_change": 0.0, "x": 520.8, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-22T23:59:59.999Z", "date": "2026-05-22", "label": "22 May 2026", "score": 50, "tone": "neutral", "raw_score": 57, "confidence": 14, "stories": 1, "close": 1640.0, "price_change": 0.0, "x": 557.2, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-05-29T23:59:59.999Z", "date": "2026-05-29", "label": "29 May 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 2, "close": 1640.0, "price_change": 0.0, "x": 593.7, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-05T23:59:59.999Z", "date": "2026-06-05", "label": "05 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 15, "stories": 2, "close": 1640.0, "price_change": 0.0, "x": 630.1, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-12T23:59:59.999Z", "date": "2026-06-12", "label": "12 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 14, "stories": 1, "close": 1640.0, "price_change": 0.0, "x": 666.5, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-19T23:59:59.999Z", "date": "2026-06-19", "label": "19 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 14, "stories": 1, "close": 1640.0, "price_change": 0.0, "x": 703.0, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 17, "stories": 2, "close": 1640.0, "price_change": 0.0, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 14, "stories": 1, "close": 1640.0, "price_change": 0.0, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 53, "confidence": 28, "stories": 6, "close": 1640.0, "price_change": 0.0, "x": 812.3, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 26, "stories": 7, "close": 1640.0, "price_change": 0.0, "x": 848.7, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 9, "close": 1640.0, "price_change": 0.0, "x": 885.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 26, "stories": 12, "close": 2500.0, "price_change": 52.4, "x": 921.6, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 29, "stories": 14, "close": 1640.0, "price_change": -34.4, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "price_path": "42.0,185.7 78.4,200.1 114.9,200.1 151.3,200.1 187.7,200.1 224.2,200.1 260.6,200.1 297.0,200.1 333.5,200.1 369.9,200.1 406.3,204.2 442.8,204.2 479.2,204.2 515.6,204.2 552.0,204.2 588.5,204.2 624.9,204.2 661.3,204.2 697.8,204.2 734.2,204.2 770.6,204.2 807.1,204.2 843.5,204.2 879.9,204.2 916.4,55.8 952.8,204.2", "sentiment_path": "120.1,128.2 156.5,130.0 192.9,130.0 229.4,130.0 265.8,130.0 411.5,130.0 448.0,130.0 484.4,130.0 520.8,130.0 557.2,130.0 593.7,130.0 630.1,130.0 666.5,130.0 703.0,130.0 739.4,130.0 775.8,130.0 812.3,128.2 848.7,130.0 885.1,130.0 921.6,130.0 958.0,130.0", "score_version": "evidence-v7", "price_change": -6.1, "sentiment_change": -1, "recent_pairs": [{"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 29, "stories": 14, "close": 1640.0, "price_change": -34.4, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 26, "stories": 12, "close": 2500.0, "price_change": 52.4, "x": 921.6, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 9, "close": 1640.0, "price_change": 0.0, "x": 885.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 26, "stories": 7, "close": 1640.0, "price_change": 0.0, "x": 848.7, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 53, "confidence": 28, "stories": 6, "close": 1640.0, "price_change": 0.0, "x": 812.3, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 14, "stories": 1, "close": 1640.0, "price_change": 0.0, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 17, "stories": 2, "close": 1640.0, "price_change": 0.0, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-19T23:59:59.999Z", "date": "2026-06-19", "label": "19 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 14, "stories": 1, "close": 1640.0, "price_change": 0.0, "x": 703.0, "y": 130.0, "show_label": false, "label_y": 120.0}], "reconstructed": true, "latest_close": 1640.0, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug", "live_score_version": "evidence-v7", "comparable_to_live": true}, "sentiment_history": [{"label": "23 Feb 23:59", "short_label": "23 Feb", "collected_at": "2026-02-23T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "27 Feb 23:59", "short_label": "27 Feb", "collected_at": "2026-02-27T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 3, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "21 Apr 23:59", "short_label": "21 Apr", "collected_at": "2026-04-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -2, "tone": "neutral", "height": 4, "articles": 1, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "13 May 23:59", "short_label": "13 May", "collected_at": "2026-05-13T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "28 May 23:59", "short_label": "28 May", "collected_at": "2026-05-28T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 2, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 2, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 2, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Jul 23:59", "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 4, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Jul 23:59", "short_label": "08 Jul", "collected_at": "2026-07-08T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 9, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 15, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": -1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 12, "article_change": 8, "tone": "neutral", "height": 4, "articles": 22, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 22, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": 12, "score_change_display": "+12", "confidence_change": 15, "article_change": 11, "tone": "positive", "height": 24, "articles": 33, "confidence": 55, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": 4, "score_change_display": "+4", "confidence_change": 4, "article_change": 9, "tone": "positive", "height": 32, "articles": 42, "confidence": 59, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 9, "tone": "positive", "height": 32, "articles": 51, "confidence": 60, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "13 Aug 14:09", "short_label": "13 Aug", "collected_at": "2026-08-13T14:09:00.295273+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "positive", "height": 32, "articles": 52, "confidence": 58, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v7", "live_version": "evidence-v7", "comparable_to_live": true, "reconstructed": true, "observations": 27, "span_label": "171 days", "first_score": 52, "latest_score": 66, "net_change": 14, "net_change_display": "+14", "direction": "Strengthening", "high_score": 66, "low_score": 48, "latest_confidence": 58, "confidence_change": 29, "latest_articles": 52, "article_change": 51, "latest_label": "13 Aug 14:09", "latest_evidence_label": "Measured", "chart_rows": [{"label": "23 Feb 23:59", "short_label": "23 Feb", "collected_at": "2026-02-23T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 42.0, "y": 131.4}, {"label": "27 Feb 23:59", "short_label": "27 Feb", "collected_at": "2026-02-27T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 3, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 77.2, "y": 133.2}, {"label": "21 Apr 23:59", "short_label": "21 Apr", "collected_at": "2026-04-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -2, "tone": "neutral", "height": 4, "articles": 1, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 112.5, "y": 135.0}, {"label": "13 May 23:59", "short_label": "13 May", "collected_at": "2026-05-13T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 147.7, "y": 135.0}, {"label": "28 May 23:59", "short_label": "28 May", "collected_at": "2026-05-28T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 2, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 182.9, "y": 135.0}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 2, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 218.2, "y": 135.0}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 2, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 253.4, "y": 135.0}, {"label": "07 Jul 23:59", "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 4, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 288.6, "y": 131.4}, {"label": "08 Jul 23:59", "short_label": "08 Jul", "collected_at": "2026-07-08T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 323.8, "y": 133.2}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 359.1, "y": 133.2}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 394.3, "y": 135.0}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 429.5, "y": 135.0}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 464.8, "y": 135.0}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 9, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 500.0, "y": 135.0}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 535.2, "y": 135.0}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 570.5, "y": 135.0}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 605.7, "y": 135.0}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 640.9, "y": 135.0}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 676.2, "y": 135.0}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 15, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 711.4, "y": 135.0}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": -1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 746.6, "y": 135.0}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 12, "article_change": 8, "tone": "neutral", "height": 4, "articles": 22, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 781.8, "y": 138.6}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 22, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 817.1, "y": 135.0}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": 12, "score_change_display": "+12", "confidence_change": 15, "article_change": 11, "tone": "positive", "height": 24, "articles": 33, "confidence": 55, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 852.3, "y": 113.2}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": 4, "score_change_display": "+4", "confidence_change": 4, "article_change": 9, "tone": "positive", "height": 32, "articles": 42, "confidence": 59, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 887.5, "y": 105.9}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 9, "tone": "positive", "height": 32, "articles": 51, "confidence": 60, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 922.8, "y": 105.9}, {"label": "13 Aug 14:09", "short_label": "13 Aug", "collected_at": "2026-08-13T14:09:00.295273+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "positive", "height": 32, "articles": 52, "confidence": 58, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 958.0, "y": 105.9}], "chart_points": "42.0,131.4 77.2,133.2 112.5,135.0 147.7,135.0 182.9,135.0 218.2,135.0 253.4,135.0 288.6,131.4 323.8,133.2 359.1,133.2 394.3,135.0 429.5,135.0 464.8,135.0 500.0,135.0 535.2,135.0 570.5,135.0 605.7,135.0 640.9,135.0 676.2,135.0 711.4,135.0 746.6,135.0 781.8,138.6 817.1,135.0 852.3,113.2 887.5,105.9 922.8,105.9 958.0,105.9", "changes": [{"label": "13 Aug 14:09", "short_label": "13 Aug", "collected_at": "2026-08-13T14:09:00.295273+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "positive", "height": 32, "articles": 52, "confidence": 58, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 9, "tone": "positive", "height": 32, "articles": 51, "confidence": 60, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": 4, "score_change_display": "+4", "confidence_change": 4, "article_change": 9, "tone": "positive", "height": 32, "articles": 42, "confidence": 59, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": 12, "score_change_display": "+12", "confidence_change": 15, "article_change": 11, "tone": "positive", "height": 24, "articles": 33, "confidence": 55, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 22, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 12, "article_change": 8, "tone": "neutral", "height": 4, "articles": 22, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": -1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 15, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}